The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates

[1]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[2]  R. Mach,et al.  TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death , 2019, Cell Death Discovery.

[3]  R. Mach,et al.  Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex , 2018, Scientific Reports.

[4]  L. Lannfelt,et al.  Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers , 2018, Acta Neuropathologica.

[5]  John L. Robinson,et al.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.

[6]  R. Mach,et al.  The PGRMC1 Protein Level Correlates with the Binding Activity of a Sigma-2 Fluorescent Probe (SW120) in Rat Brain Cells , 2016, Molecular Imaging and Biology.

[7]  Thomas Wisniewski,et al.  Clearance systems in the brain—implications for Alzheimer disease , 2015, Nature Reviews Neurology.

[8]  Ruth Nussinov,et al.  Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s , 2015, Nature Structural &Molecular Biology.

[9]  J. Trojanowski,et al.  Spreading of pathology in neurodegenerative diseases: a focus on human studies , 2015, Nature Reviews Neuroscience.

[10]  Gary Look,et al.  Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity , 2014, PloS one.

[11]  Miles Miller,et al.  Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits , 2014, PloS one.

[12]  Murray Grossman,et al.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank , 2014, Alzheimer's & Dementia.

[13]  Martin Hallbeck,et al.  Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance , 2014, Neurobiology of Disease.

[14]  R. Mach,et al.  The σ2 receptor: a novel protein for the imaging and treatment of cancer. , 2013, Journal of medicinal chemistry.

[15]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[16]  Björn Granseth,et al.  Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of β-Amyloid , 2012, The Journal of Neuroscience.

[17]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[18]  G. Bu,et al.  Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Mediates Neuronal Aβ42 Uptake and Lysosomal Trafficking , 2010, PloS one.

[19]  E. Capetillo-Zarate,et al.  Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease , 2010, Acta Neuropathologica.

[20]  Roberto Malinow,et al.  Amyloid beta from axons and dendrites reduces local spine number and plasticity , 2010, Nature Neuroscience.

[21]  K. Reymann,et al.  Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity , 2010, Proceedings of the National Academy of Sciences.

[22]  Jin-Moo Lee,et al.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide , 2009, Proceedings of the National Academy of Sciences.

[23]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[24]  M. Findeis.  The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .

[25]  H. Gruppen,et al.  Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. , 2007, Journal of agricultural and food chemistry.

[26]  P. Verkade,et al.  Alzheimer's disease beta-amyloid peptides are released in association with exosomes. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Mach,et al.  Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. , 2006, Nuclear medicine and biology.

[28]  R. Mach,et al.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. , 2005, European journal of pharmacology.

[29]  B. Leonard.  Sigma Receptors and Sigma Ligands: Background to a Pharmacological Enigma , 2004, Pharmacopsychiatry.

[30]  J. Buxbaum,et al.  Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome , 2004, Neurobiology of Aging.

[31]  G. Cole,et al.  Apolipoprotein E enhances uptake of soluble but not aggregated amyloid‐β protein into synaptic terminals , 2003, Journal of neurochemistry.

[32]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[33]  P. A. Peterson,et al.  Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease , 2001, Histopathology.

[34]  A. Roher,et al.  Evidence for Seeding of β-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in β-Amyloid Precursor Protein-Transgenic Mice , 2000, The Journal of Neuroscience.

[35]  W. Bowen.  Sigma receptors: recent advances and new clinical potentials. , 2000, Pharmaceutica acta Helvetiae.

[36]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[37]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[38]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Pericak-Vance,et al.  Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[41]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[42]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.

[43]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[45]  L. Jungbauer,et al.  Preparing synthetic Aβ in different aggregation states. , 2011, Methods in molecular biology.

[46]  M. Findeis.  The role of amyloid beta peptide 42 in Alzheimer's disease. , 2007, Pharmacology & therapeutics.

[47]  J. Buxbaum,et al.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. , 2004, Neurobiology of aging.

[48]  D. Butterfield.  Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. , 2002, Free radical research.

[49]  P. Greengard,et al.  Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.

[50]  A. Roher,et al.  Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[52]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[53]  I. AndreaLeBlanc.  The role of -amyloid peptide in alzheimer's disease , 1994 .

[54]  R. Mahley,et al.  Lipoprotein-receptor interactions. , 1986, Methods in enzymology.